OneAscent Wealth Management LLC Purchases 200 Shares of STERIS plc (NYSE:STE)

OneAscent Wealth Management LLC raised its position in STERIS plc (NYSE:STE) by 7.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,856 shares of the medical equipment provider’s stock after purchasing an additional 200 shares during the period. OneAscent Wealth Management LLC’s holdings in STERIS were worth $693,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC bought a new stake in STERIS in the third quarter valued at approximately $25,000. Central Pacific Bank Trust Division bought a new stake in STERIS in the third quarter valued at approximately $28,000. Quent Capital LLC increased its position in shares of STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 71 shares in the last quarter. Versant Capital Management Inc increased its position in shares of STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 181 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in shares of STERIS by 154.7% during the second quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

STE stock traded up $0.21 during mid-day trading on Monday, hitting $220.33. The stock had a trading volume of 33,692 shares, compared to its average volume of 490,629. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. STERIS plc has a 52 week low of $195.47 and a 52 week high of $248.24. The firm has a market capitalization of $21.75 billion, a P/E ratio of 50.26 and a beta of 0.85. The firm has a fifty day simple moving average of $230.37 and a 200 day simple moving average of $228.59.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the firm earned $2.03 EPS. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, research analysts forecast that STERIS plc will post 9.15 EPS for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.03%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Activity at STERIS

In related news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 35.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

STE has been the subject of several research reports. JMP Securities reissued a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. KeyCorp increased their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $253.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.